The MINDACT trial: The first prospective clinical validation of a genomic tool-Reference-Cited by-同舟云学术

The MINDACT trial: The first prospective clinical validation of a genomic tool

Published:2007-10-22 Issue:3 Volume:1 Page:246-251
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:

Author:

Cardoso Fatima,Piccart-Gebhart Martine,Veer Laura Van't,Rutgers Emiel

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Reference23 articles.

1. Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools;Ach;BMC Genomics,2007

2. Prospective evaluation of a gene signature as a new prognostic tool in early stage breast cancer: background and challenges in the design of MINDACT (Microarray In Node negative Disease May Avoid Chemotherapy Trial);Bogaerts;Nat. Clin. Pract. Oncol.,2006

3. Feasibility of gene expression profiling in community hospitals; preliminary results of a pilot study in N0 breast cancer patients;Bueno de Mesquita;Breast Cancer Res. Treat.,2005

4. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer;Buyse;J. Natl. Cancer Inst.,2006

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing clinical decision support with genomic tools in breast cancer: A Scottish perspective;The Breast;2024-06

2. Using MammaPrint on core needle biopsy to guide the need for axillary staging during breast surgery;Surgery;2024-03

3. NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence;Clinical and Translational Medicine;2024-02

4. Invasive Carcinomas of the Breast;Tumors of the Mammary Gland;2024-01

5. Modified IHC4 score predicts prognosis but not chemotherapy survival benefit in young women with HR-positive, HER2-negative early breast cancer: A Hospital-Based Cohort study;2023-12-23